Liang Cheng, President of International Society of Urological Pathology, Vice Chair for Translational Research at the Warren Alpert Medical School of Brown University, shared a post on X:
“Excited to share two recent high-impact publications from Dr. Zhiping Wang’s lab, and truly honored to be part of these important studies advancing the landscape of precision oncology and FGFR3-targeted therapy in bladder cancer.
In our Advanced Science study (PMID: 41168906, journal impact factor, 14), Dr. Wang and colleagues developed a novel FGFR3-targeting antibody–drug conjugate (ADC) delivering a potent camptothecin derivative (A2) directly to tumor cells. Beyond precise targeting, this work uncovers a compelling mechanism – activation of the cGAS – STING pathway, linking targeted therapy with innate immune signaling. The ADC demonstrated strong efficacy in patient-derived organoids and xenograft models, including chemotherapy-resistant disease, with a favorable safety profile.
Complementing this, our Journal of Nanobiotechnology study (PMID: 41275281, journal impact factor, 12) introduces a precision nanotherapeutic platform enabling ultrasound-triggered intratumoral generation of cytotoxic agents. This innovative system integrates sonodynamic therapy, redox modulation, and programmed cell death (including pyroptosis), achieving spatially controlled tumor targeting while minimizing systemic toxicity.
Together, these studies highlight key advances in bladder cancer therapeutics:
- Transition from conventional targeting to precision delivery platforms (ADC, nanomedicine)
- Integration of mechanistic biology with therapeutic design (STING activation, oxidative stress, pyroptosis)
- Overcoming resistance through multimodal and microenvironment-responsive strategies
- Expanding the clinical relevance of FGFR3 as a key actionable target
Precision oncology is clearly entering a new phase -driven not only by molecular targets, but by innovative therapeutic engineering and deeper biologic insight. Grateful to be part of these outstanding collaborative efforts in advancing precision care of bladder cancer patients.”
Title: A Novel FGFR3-Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS-STING Pathway in Bladder Cancer
Authors: Shu Cui, Xiongfei Luo, Guangrui Fan, Jingqi Jiang, Yingru Wang, Enguang Yang, Jinpeng Ma, Ze Zhang, Yuhan Wang, Juan Wang, Dengtuo Wang, Hanzhang Wang, Liang Cheng, Junqiang Tian, Zhilong Dong, Yingqian Liu, Zhiping Wang
Read the Full Article.
Title: A novel sono-activatable nanoreactor induces precision intratumoral juglone generation and caspase 3/GSDME-mediated pyroptosis for treatment of bladder cancer
Authors: Yuanfeng Zhang, Enguang Yang, Xinyu Zhang, Yibo Shi, Guangrui Fan, Yuhan Wang, Junqiang Tian, Hanzhang Wang, Zhilong Dong, Yingru Wang, Liang Cheng, Zhiwen Zhao, Yonghai Zhang, Baodui Wang, Zhiping Wang
Read the Full Article.
Other articles featuring Liang Cheng on OncoDaily.
